Fig. 3.

Rates of LDA and remission at week 12

Patients achieving (A) DAS28-4(CRP) ≤3.2 and LDA based on DAS28-4(ESR), CDAI and SDAI definitions and (B) DAS28-4(CRP) <2.6 and remission based on DAS28-4(ESR), CDAI and SDAI definitions at week 12 (FAS, NRI). *P<0.05; **P<0.01; ***P<0.001 vs tofacitinib IR 5 mg BID [P-values were not adjusted for multiplicity]. Rates of remission and LDA based on SDAI, CDAI and ACR-EULAR Boolean criteria were analysed post hoc. BID: twice daily; CDAI: Clinical Disease Activity Index; DAS28-4: DAS in 28 joints; FAS: full analysis set; IR: immediate-release; LDA: low disease activity; MR: modified-release; NRI: non-responder imputation; QD: once daily; SDAI: Simplified Disease Activity Index.